Trials / Completed
CompletedNCT06151717
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
PRAGMMATIC: A Comparative Clinical Trial to Determine the BEST Initial Therapy for Multiple Myeloma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
Detailed description
PRIMARY OBJECTIVE: I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM. OUTLINE: This is an observational study. Patients have their medical records reviewed on study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional Study | Non-interventional study |
Timeline
- Start date
- 2023-09-21
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
- First posted
- 2023-11-30
- Last updated
- 2025-06-17
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06151717. Inclusion in this directory is not an endorsement.